Expert Committee on Questions of Population and Racial Policy

 aTyr Pharma Advances Development of Lead Therapeutic Candidate ATYR1923 with Announcement of “efzofitimod” as Nonproprietary Name

Retrieved on: 
Thursday, January 13, 2022
Biomarker, Forward-looking statement, Patient, Research, ATyr Pharma, SAN, International, Biology, Private Securities Litigation Reform Act, SEC, NRP2, COVID-19, Inflammation, Expert Committee on Questions of Population and Racial Policy, Sarcoidosis, Safety, Interstitial lung disease, Neuropilin, FC, USAN, GLOBE, World, Goal, LIFE, WHO, RNA transfection, INN, Risk, Immune system, United States Adopted Name, Annual report, Pharmaceutical industry

By restoring immune balance through selective modulation of NRP2, efzofitimod is the first tRNA synthetase-derived and NRP2-targeting therapy to demonstrate clinical activity in patients.

Key Points: 
  • By restoring immune balance through selective modulation of NRP2, efzofitimod is the first tRNA synthetase-derived and NRP2-targeting therapy to demonstrate clinical activity in patients.
  • We look forward to initiating a registrational trial of efzofitimod in our lead indication, pulmonary sarcoidosis, this year.
  • The USAN Council and WHO are responsible for selecting simple, informative and unique nonproprietary (generic) drug names.
  • aTyr is developing efzofitimod as a potential therapeutic for patients with severe inflammatory lung diseases.

Bo'ao Winhealth Rare Disease Medical Center and Ali Health Jointly Launched the "Global Drug Information Platform for Rare Diseases"

Retrieved on: 
Monday, September 27, 2021
Policy, Review, Chinese Academy of Sciences, Degenerative disease, Expert Committee on Questions of Population and Racial Policy, Senior, Center, Founder, Statistics, Big data, Safety, Biotechnology, Food, Kyowa Hakko Kirin, Health, CEO, Group, Security, FSMP, Disease, Incidence, Cloud computing, Partnership, ICF, WeChat, Daiichi Sankyo, Diagnosis, Treatment, Alibaba Group, WHO, Hope, Platform, Hospital, Patient, Glycerol phenylbutyrate, AI, IOT, NGO, Muhammad Ali Center, Medical device, Pharmaceutical industry

Jointly built by Bo'ao Winhealth Rare Disease Medical Center and Ali Health, the Platform aims at addressing the challenges of unavailability and unaffordability of the overseas innovative therapies facing the Chinese patients with rare diseases.

Key Points: 
  • Jointly built by Bo'ao Winhealth Rare Disease Medical Center and Ali Health, the Platform aims at addressing the challenges of unavailability and unaffordability of the overseas innovative therapies facing the Chinese patients with rare diseases.
  • "The Global Drug Information Platform for Rare Diseases is an effective exploration by multiple parties for the construction of support system for rare diseases.
  • The special policy of Boao Lecheng Pilot Zone and Bo'ao Winhealth Rare Disease Medical Center offer hope for patients.
  • For more information, please follow "Bo'ao Winhealth Rare Disease Medical Center" on Wechat.